Trial Search Results

A Study of Galcanezumab in Participants With Chronic Cluster Headache

The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic cluster headache.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company

Stanford Investigator(s):


  • Drug: Galcanezumab 300 mg
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Participants with a history of chronic cluster headache occurring without a remission
   period, or with remissions lasting <1 month, for at least 1 year.

   - Participants are able to distinguish cluster headache attacks from other headaches.

Exclusion Criteria:

   - Current enrollment in or discontinuation within the last 30 days from, a clinical
   trial involving any investigational drug or device.

   - Current use or any prior exposure to any calcitonin-gene-related peptide (CGRP)
   antibody, any antibody to the CGRP receptor, or antibody to nerve growth factor (NGF).

   - Are taking indomethacin and/or are suspected of having another distinct trigeminal
   autonomic cephalalgia.

   - A history of migraine variants that could implicate or could be confused with

   - Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic

   - A history or presence of other medical illness that indicates a medical problem that
   would preclude study participation.

   - Evidence of significant active or unstable psychiatric disease, in the opinion of the

   - Women who are pregnant or nursing.

Ages Eligible for Study

18 Years - 65 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305